Statement: The majority of the primary trial participants achieved CR or PR.
Primary_evidence: Outcome Measurement:    Objective Response Rate (ORR)   Tumor response evaluation was performed using RECIST 1.0 using CT/MRI. Proportion of patients achieving a CR or PR is considered in the overall response.   Time frame: Assessed at the end of each even-numbered cycle (every 8 weeks), or per standard of care but no less than 4 weeks and nor more than every 12 weeks (+/- 1 week) if treatment has ended. Results 1:    Arm/Group Title: Pralatrexate   Arm/Group Description: Study drug 190 mg/m^2 for 2 to 4 weeks.   Overall Number of Participants Analyzed: 22   Measure Type: Number   Unit of Measure: participants  1